Meglumine antimoniate contraindications: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi (talk | contribs) (Created page with "__NOTOC__ {{Meglumine antimoniate}} {{CMG}} <ref>{{Cite web | last = | first = | title = WHO Model Prescribing Information: Drugs Used in Parasitic Diseases - Second E...") |
Gerald Chi (talk | contribs) mNo edit summary |
||
Line 3: | Line 3: | ||
{{CMG}} | {{CMG}} | ||
==Contraindications== | |||
Severe kidney, heart or liver disorders.<ref>{{Cite web | last = | first = | title = WHO Model Prescribing Information: Drugs Used in Parasitic Diseases - Second Edition: Protozoa: Leishmaniasis: Meglumine antimoniate and sodium stibogluconate | url = http://apps.who.int/medicinedocs/en/d/Jh2922e/2.4.1.html#Jh2922e.2.4.1 | publisher = | date = | accessdate = }}</ref> | |||
<ref>{{Cite web | last = | first = | title = WHO Model Prescribing Information: Drugs Used in Parasitic Diseases - Second Edition: Protozoa: Leishmaniasis: Meglumine antimoniate and sodium stibogluconate | url = http://apps.who.int/medicinedocs/en/d/Jh2922e/2.4.1.html#Jh2922e.2.4.1 | publisher = | date = | accessdate = }}</ref> | |||
==References== | ==References== |
Latest revision as of 03:41, 7 January 2014
Meglumine Antimoniate |
---|
GLUCANTIM® WHO Prescribing Information |
Description |
Indications and Usage |
Contraindications |
Warnings and Precautions |
Adverse Reactions |
Dosage and Administration |
How Supplied |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Contraindications
Severe kidney, heart or liver disorders.[1]
References
Adapted from the FDA Package Insert.